VivoSeq
Other

Sexual Function

0

Pipeline Programs

0

Active Trials

2

Companies Involved

Sexual Function is an early-stage landscape with 0 programs across 2 companies. The most active players are GSK, Takeda.

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

8/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

13

clinical trials

Completed12 · 92%
Terminated1 · 8%

Trial Activity

13 trials

Statin Lowering Testosterone and Sexual Function
Completed··Phase 4·NCT02612714·151 enrolled
Effects Of Antidepressants On Sexual Functioning In Adults
Completed·GSK logoGSK·Phase 3·NCT00051272·425 enrolled
Prospective Sexual Function Study for BPH Subjects
Completed·GSK logoGSK·Phase 4·NCT01777269·489 enrolled
Effects of Antidepressants on Sexual Functioning
Completed·GSK logoGSK·Phase 3·NCT00051259·420 enrolled
Sexual Functioning Study With Antidepressants
Completed·GSK logoGSK·Phase 4·NCT00316160·347 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)